Greenyn Biotechnology Co., Ltd
6846
Rank in Stocks
#23879
Greenyn Biotechnology Co., Ltd is an enterprise specializing in dietary... Greenyn Biotechnology Co., Ltd is an enterprise specializing in dietary supplements, dedicated to the development, production, and worldwide distribution of health-enhancing products. Their product portfolio includes a range of proprietary active ingredients. These feature notable components such as Insumate, derived from bitter melon extract; Antromax, which utilizes antrodia cinnamomea; and the Zymologist 101 Phyto fermented drink. Beyond individual ingredients, Greenyn provides an extensive selection of functional product series catering to a diverse array of health and wellness needs. These encompass solutions for youth and beauty, digestive and brain health, overall body regulation, throat care, hair care, vision support, and various lifestyle enhancement formulas. Additional ranges include joint health, general nutritional and energy supplementation, immune modulation, low-burden options, sleep assistance, body contouring, circulatory support, specific formulas for men's vitality and women's intimate health, and dedicated products for mature women. Moreover, the company extends its expertise through various services, including custom product development, Original Design Manufacturing (ODM), dosage form optimization, and application support. Established in 2012, the firm's operations are headquartered in Taichung, Taiwan.
Share Price
$1.40
Last synced: 2026-11-10
Market Cap
$37.91M
Change (1 day)
-9.01%
Change (1 year)
-42.65%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Greenyn Biotechnology Co., Ltd (6846)
Category
Healthcare
EPS for Greenyn Biotechnology Co., Ltd (6846)
EPS as of June 2026 TTM: $0.15
According to Greenyn Biotechnology Co., Ltd's latest financial reports, its current EPS (TTM) is $0.15. At the end of 2025 the company had an EPS of $0.17, equal to its 2024 EPS of $0.17.
EPS history for Greenyn Biotechnology Co., Ltd from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.15 | -14.65% |
| 2025 | $0.17 | 3.43% |
| 2024 | $0.17 | 1.03% |
| 2023 | $0.16 | -16.17% |
| 2022 | $0.20 | -0.51% |
| 2021 | $0.20 | 3.47% |
| 2020 | $0.19 | 38.27% |
| 2019 | $0.14 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | 10,692.56% |
US
|
|
| $-7.07 | -4,972.50% |
US
|
|
| $-5.29 | -3,745.76% |
AU
|
|
| $12.88 | 8,776.71% |
BE
|
|
| $21.56 | 14,758.72% |
NL
|
Questions about Greenyn Biotechnology Co., Ltd's earnings per share (EPS)
What is Greenyn Biotechnology Co., Ltd's earnings per share (EPS)?
Greenyn Biotechnology Co., Ltd's earnings per share (EPS) over the last twelve months is $0.15, as of Jun 2026.
What was Greenyn Biotechnology Co., Ltd's earnings per share (EPS) in 2025?
In 2025, Greenyn Biotechnology Co., Ltd's earnings per share (EPS) was $0.17, about the same as in 2024 ($0.17).
How has Greenyn Biotechnology Co., Ltd's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Greenyn Biotechnology Co., Ltd's earnings per share (EPS) went from $0.19 to $0.17, an average decline of 2.20% a year.
How does Greenyn Biotechnology Co., Ltd's earnings per share (EPS) compare with similar companies?
Greenyn Biotechnology Co., Ltd's earnings per share (EPS) ($0.15) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.